Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis Media ReleaseCarolyn MillerOctober 19, 2021Blade Therapeutics, Paul Kelly
Blade Therapeutics Announces FDA Orphan Drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis Media ReleaseCarolyn MillerOctober 14, 2021Blade Therapeutics, Paul Kelly
Blade Therapeutics Mourns the Passing of General Counsel and Secretary Alan C. Mendelson Media ReleaseCarolyn MillerOctober 11, 2021Blade Therapeutics
Blade Therapeutics Announces Publication of Preclinical Evidence Supporting Neuroprotective Effects of Proprietary Calpain Inhibitor in a Rare Inherited Neurodegenerative Disease Media ReleaseCarolyn MillerOctober 8, 2021Blade Therapeutics, Paul Kelly
Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients with COVID-19 Pneumonia Media ReleaseCarolyn MillerAugust 13, 2020Blade Therapeutics, Paul Kelly
Blade Therapeutics Appoints Accomplished Biopharmaceutical Executive, Mark Timney, as Chairman of the Board Media ReleaseCarolyn MillerAugust 10, 2020Blade Therapeutics, Paul Kelly
Blade Therapeutics announces publication of preclinical data supporting Calpain 9 as a promising therapeutic target for fibriotic disease Media ReleaseCarolyn MillerAugust 21, 2019Paul Kelly, Blade Therapeutics
